Table 2 Characteristics of patients eligible for RIOP and TARGIT A trials of the G3S (R1E and T1E), cohort 2(R2E and T2E) cohorts and of the patients included in the TARGIT A trial, TARGIT arm

n

1593/7580 (21%)

4036/7580 (53.2%)

356/4445 (8%)

1509/4445 (33.9%)

996/1113 (89.5%)

Age

< 45 years

0

1813 (30.3%)

0/356 (0%)

0/1509 (0%)

17/1113 (2%)

45-54 years

0

1216 (20.3%)

0/356 (0%)

459/1509 (30.4%)

212/1113 (19%)

≥55 years

1593 (100%)

2958 (49.4%)

356/356 (100%)

1050/1509 (69.6%)

884/1113 (80%)

Tumor size

≤20 mm

1593/1593 (100%)

3674/4036 (91%)

356/356 (100%)

1185/1508 (78.6%)

912/1056 (86%)

>20 mm

0/1593 (0%)

362/4036 (9%)

0/356 (0%)

323/1508 (21.2%)

144/1056 (14%)

Histology

Ductal

1391/1593 (87.3%)

3596/4036 (89.1%)

356/356 (100%)

1509/1509 (100%)

1012/1070 (95%)

Lobular

0/1593 (0%)

0/4036 (0%)

0/356 (0%)

0/1509 (0%)

47/1070 (4%)

Mixed

0/1593 (0%)

0/4036 (0%)

0/356 (0%)

0/1509 (0%)

32/1070 (3%)

Colloids, ductal medullary

202/1593 (12.7%)

440/4036 (10.9%)

0/356 (0%)

0/1509 (0%)

Grade

1

931/1593 (58.4%)

1775/3988 (44%)

211/356 (59.3%)

604/1465 (41.2%)

341/1040 (33%)

2

662/1593 (41.6%)

1582/3988 (39.2%)

145/356 (40.7%)

620/1465 (42.3%)

540/1040 (52%)

3

0/1593 (0%)

631/3988 (15.6%)

0/356 (0%)

241/1465 (16.5%)

159/1040 (15%)

pN

0

1593/1593 (100%)

4036/4036 (100%)

356/356 (100%)

1509/1509 (100%)

866/1059 (82%)

1 -3

0/1593 (0%)

0/4036 (0%)

0/356 (0%)

0/1509 (0%)

155/1059 (15%)

>3

0/1593 (0%)

0/4036 (0%)

0/356 (0%)

0/1509 (0%)

54/1059 (4%)

RH

+

1593/1593 (100%)

3537/4036 (87.6%)

356/356 (100%)

851/1499 (56.8%)

962/1063 (90%)

-

0/1593 (0%)

499/4036 (12.4%)

0/356 (0%)

648/1499 (43.2%)

101/1063 (10%)

EVPT

Absent

1593/1593 (100%)

3056/3389 (90.2%)

356/356 (100%)

1081/1391 (77.7%)

881/1022 (86%)

Present

0/1593 (0%)

333/3389 (9.8%)

0/356 (0%)

310/1391 (22.3%)

141/1022 (14%)

Excision limits

Healthy

1593/1593 (100%)

4036/4036 (100%)

356/356 (100%)

1509/1509 (100%)

970/1072 (90.5%)

Unhealthy

0/1593 (0%)

0/4036 (0%)

0/356 (0%)

0/1509 (0%)

102/1072 (9.5%)

Multifocality

No

1593/1593 (100%)

4036/4036 (100%)

356/356 (100%)

1509/1509 (100%)

Yes

0/1593 (0%)

0/4036 (0%)

0/356 (0%)

0/1509 (0%)

Chemotherapy

No

1387/1469 (94.4%)

802/3834 (20.9%)

317/356 (89%)

1146/1509 (76%)

997/1113 (90%)

Yes

82/1469 (5.6%)

3032/3834 (79.1%)

39/356 (11%)

363/1509 (24%)

116/1113 (10%)

Hormonal therapy

Yes

1426/1589 (89.7%)

3290/4026 (81.7%)

356/356 (100%)

851/1499 (56.8%)

727/1113 (65%)

No

163/1589 (10.3%)

736/4026 (18.3%)

0/356 (0%)

648/1499 (43.2%)

386/1113 (35%)

Radiothery boost to tumor bed

Yes

318/355 (89.6%)

1316/1461 (90%)

No

37/355 (10.4%)

145/1461 (10%)

Boost dose

<20Gy

305/313 (97.4%)

1156/1298 (89%)

≥20Gy

8/313 (2.6%)

142/1298 (11%)